Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

An analysis of Phase 3 data presented by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) of its Alzheimer's therapy Aduhelm (aducanumab) showed the treatment slowed cognitive, functional, and behavioral decline in the early stages of the disease. Treatment effects were exhibited across all three cognitive and three functional domains measured by Clinical Dementia Rating-Sum of Boxes (CDR-SB), the EMERGE study's primary endpoint.

Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients

Aduhelm was approved by the FDA for Alzheimer's disease. Controversy about that decision has knocked down Biogen's stock price.

Biogen's Case For Aduhelm For Alzheimer's

Ionis Pharma

Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC

CAMBRIDGE, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its Alzheimer's disease (AD) research portfolio, will contribute four virtual posters that showcase data from its clinical trials with ADUHELM™ (aducanumab-avwa) injection 100 mg/mL solution at the Alzheimer's Association International Conference (AAIC), being held in Denver, Colo. and virtually from July 26-30, 2021,

Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021

The company is moving into three billion-dollar areas.

Could These 3 Potential Blockbusters Transform Biogen?

CAMBRIDGE, Mass., July 23, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will share multiple oral and poster presentations from its Alzheimer's disease clinical development portfolio at the Alzheimer's Association International Conference (AAIC), which will be held in Denver, Colorado and online July 26-30, 2021. The company's contributions to AAIC will include several presentations highlighting data on ADUHELM™ (aducanumab-avwa) injection 100 mg/mL solution, which was recently granted accelerated approval by the U.S. Food and Drug Administration (FDA) as a treatment for Alzheimer's disease, as well as its broader Alzheimer's disease portfolio and research in the field.

Biogen to Present Data from ADUHELM and Alzheimer's Disease Portfolio at 2021 Alzheimer's Association International Conference

Biogen's new — and controversial — Alzheimer's drug, Adhulem, made a modest $2 million in revenue in the first several weeks after its.

Biogen Defends Controversial Alzheimer's Drug as FDA Calls for Probe

Biogen executives sought to assure investors that the science behind its newly approved Alzheimer's disease drug is firm despite ongoing questions about whether the drug works, how it was approved, and what it costs.

Biogen, under pressure, tells investors it ‘stands by' the FDA review process for its Alzheimer's drug

Biogen (NASDAQ: BIIB) launched in June a new Alzheimer's disease drug but its uptake so far has been slow, leading one notable Wall Street analyst to recommend a cautious approach towards the stock. Cost of Biogen's Alzheimer's treatment criticized There is a debate currently regarding the high cost of the drug, which is $56,000, and […] The post Biogen‘s Alzheimer treatment triggers debate regarding its real-world benefits appeared first on Invezz.

Biogen‘s Alzheimer treatment triggers debate regarding its real-world benefits

Biogen Inc. (BIIB) CEO Michel Vounatsos on Q2 2021 Results - Earnings Call Transcript

The figure was below the $6.3 million analysts surveyed by FactSet expected, but the gap is relatively small for a drug expected to bring in billions.

Biogen Sold $1.6M of Aduhelm in Weeks After Approval. Earnings Were Strong.

Biogen (BIIB) beats second-quarter estimates for both earnings and sales and ups sales guidance for 2021.

Biogen (BIIB) Q2 Earnings Top, Aduhelm Early Sales Hit $2M

Biotech giant Biogen said that it brought in about $1.6 million in sales from its controversial Alzheimer's drug last month after it was approved by the Food and Drug Administration earlier in June.

Biogen's controversial Alzheimer's drug made $1.6M in revenue in June

Shares of Biogen (NASDAQ:BIIB) fell 0.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 44.64% over the past year to $5.68, which beat the estimate of $4.55.

Biogen: Q2 Earnings Insights

Biogen's Alzheimer's drug, Adhulem, generated $2 million in revenue in the first few weeks of its approval, the company said in its second-quarter earnings.

Biogen's controversial Alzheimer's drug generates $2 million in first few weeks after approval

Shares of Biogen gained 1.6% in premarket trading on Thursday after the company beat expectations for the second quarter and disclosed that it's already sold $2 million of its new, controversial Alzheimer's disease drug. Biogen had earnings of $448.5 million, or $2.99 per share, in the second quarter of 2021, compared to $1.5 billion, or $9.59 per share, in the same quarter a year ago.

Biogen's beats on earnings, says it's also brought in $2 million in sales of Alzheimer's drug

Biogen Inc (NASDAQ: BIIB) posted Q2 adjusted EPS of $5.68 ahead of the consensus estimate of $4.55, but quarterly profit fell around 71% Y/Y to $448.5 million as competition intensified for the Company's flagship product, Tecfidera, a multiple sclerosis drug. Though sales of $2.8 billion came in above expectation of $2.6 billion, it decreased 25% Y/Y at actual currency and decreased 26% at constant currency.

Biogen's Q2 Profit Falls 70% As Tecfidera Competition Hits Topline

Biogen Inc on Thursday reported a 70.9% fall in quarterly profit as competition intensifies for multiple sclerosis drug Tecfidera, once the company's flagship treatment.

Biogen profit tumbles 71% on rising competition to multiple sclerosis drug

NOTE: ADUHELM TM (aducanumab-avwa) injection 100 mg/mL solution is indicated for the treatment of Alzheimer's disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied. This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). Please see full Prescribing Information including Medication Guide .

An open letter to the Alzheimer's disease community from our Head of Research and Development, Alfred Sandrock, M.D., Ph.D.

Roche Holding AG

Aduhelm is expected to be a bestseller for Biogen and was the first Alzheimer's drug to be granted “accelerated approval,” a decision the regulator's experts criticized and said there was not enough evidence the drug actually worked.

Roche Is Discussing Alzheimer's Drug With FDA Following Regulators Controversial Approval Of Biogen's Aduhelm, CEO Says

Mirimus Inc has collaborated with Biogen Inc (NASDAQ: BIIB) to develop RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications.  Terms of the collaboration are not disclosed.

Biogen, Mirimus Team Up For RNAi-Based Therapeutics For Neurological Indications

NEW YORK, July 21, 2021 /PRNewswire/ -- Mirimus, Inc., a pioneer in RNAi therapeutic design and CRISPR/Cas9 gene editing technology implementation, today announced a strategic collaboration with Biogen Inc. (NASDAQ: BIIB) focused on the development of RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications. Terms of the collaboration between Mirimus and Biogen are undisclosed.

Mirimus, Inc. Forms Strategic Collaboration with Biogen to Develop RNAi-Based Therapeutics for Neurological Disease Indications

Investor focus is likely to be on commercialization plans for new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports second-quarter earnings.

Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?

This biotech company could be a diamond in the rough -- for investors who can tolerate its share price volatility.

Is It Too Late to Buy Biogen Stock?

Piper Sandler's Christopher Raymond argues that many neurologists still plan to prescribe Aduhelm and that insurers would largely cover the therapy's cost.

News for Biogen Stock (BIIB)